UNIQUE HISTOLOGICAL-CHANGES IN LUNG METASTASES OF OSTEOSARCOMA PATIENTS FOLLOWING THERAPY WITH LIPOSOMAL MURAMYL TRIPEPTIDE (CGP-19835A LIPID)

被引:68
作者
KLEINERMAN, ES
RAYMOND, AK
BUCANA, CD
JAFFE, N
HARRIS, MB
KRAKOFF, IH
BENJAMIN, R
FIDLER, IJ
机构
[1] TOMORROWS CHILDRENS INST,HACKENSACK,NJ
[2] UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PEDIAT,HOUSTON,TX 77030
[3] UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,HOUSTON,TX 77030
[4] UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MED ONCOL,HOUSTON,TX 77030
[5] UNIV TEXAS,MD ANDERSON CANCER CTR,DIV MED,HOUSTON,TX 77030
关键词
LIPOSOMAL THERAPY; FIBROSIS;
D O I
10.1007/BF01741788
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have recently begun a phase II trial in patients with osteosarcoma who developed pulmonary metastases during adjuvant chemotherapy or who presented with pulmonary metastases that persisted despite chemotherapy. Eligible patients were rendered free of visible disease by surgery. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (MTP-PE, CGP 19835A lipid) (2 mg/m2) was infused twice weekly for 3 months. In five patients, a single tumor nodule recurred within 6 weeks after completion of therapy. These lesions were resected and submitted for pathological examination. Tissue specimens obtained after therapy were compared to those obtained before therapy. All the patients showed a histological change in the characteristics of the pulmonary tumors. In three patients, peripheral fibrosis surrounded the tumor and inflammatory cell infiltration and neovascularization were present. This is in contrast to central necrosis, with viable peripheral tumor cells and no inflammatory response observed in lesions resected following chemotherapy. In a fourth case, evidence of early fibrotic changes was found. This and the fifth case showed a change in malignant characteristics, from high grade before liposomal therapy to low grade after therapy. The present study provides evidence for a biological effect of liposomal MTP-PE.
引用
收藏
页码:211 / 220
页数:10
相关论文
共 31 条
[1]  
DANNENBERG AM, 1988, PULMONARY DISEASES D, P1821
[2]  
DELABIE J, 1990, CLIN EXP IMMUNOL, V81, P123
[3]  
DEODHAR S, 1989, J CELL PHYSL, V138, P291
[4]   ADJUVANT CHEMOTHERAPY FOR OSTEOSARCOMA - A RANDOMIZED PROSPECTIVE TRIAL [J].
EILBER, F ;
GIULIANO, A ;
ECKARDT, J ;
PATTERSON, K ;
MOSELEY, S ;
GOODNIGHT, J .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :21-26
[5]  
FIDLER IJ, 1985, CANCER RES, V45, P4714
[6]  
FIDLER IJ, 1982, CANCER RES, V42, P496
[7]  
FIDLER IJ, 1986, SITE SPECIFIC DRUG D, P111
[8]  
FIDLER IJ, 1982, YB CANCER
[9]   CORRELATION OF TUMOR-GROWTH INHIBITORY ACTIVITY OF MACROPHAGES EXPOSED TO ADRIAMYCIN AND ADRIAMYCIN SENSITIVITY OF THE TARGET TUMOR-CELLS [J].
GIAVAZZI, R ;
BUCANA, CD ;
HART, IR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1984, 73 (02) :447-455
[10]   WEEKLY HIGH-DOSE METHOTREXATE AND DOXORUBICIN FOR OSTEOSARCOMA - THE DANA-FARBER-CANCER-INSTITUTE THE CHILDRENS-HOSPITAL - STUDY-III [J].
GOORIN, AM ;
PEREZATAYDE, A ;
GEBHARDT, M ;
ANDERSEN, JW ;
WILKINSON, RH ;
DELOREY, MJ ;
WATTS, H ;
LINK, M ;
JAFFE, N ;
FREI, E ;
ABELSON, HT .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (08) :1178-1184